Alliance with this company positions PPD to a new level in oncology arena


This slideshow requires JavaScript.


Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), and NeoGenomics Laboratories, Inc., a leading provider of cancer-focused genetic testing services, have entered into an agreement to provide afully integrated global pathology and molecular testing solution to PPD’s current client base.

As part of the deal, NeoGenomics will provide a  range of lab testing services to support PPD® Laboratories’ oncology clinical trial activities globally.

Collaboration’s key focus is centralized pathology review, as well as specialty lab services, including flow cytometry, fluorescence in situ hybridization (FISH),and others.

Duo will also provide its clientele, a comprehensive companion diagnostics offering from biomarker discovery through regulatory approval and commercialization. Talk about the best bundled services in oncology space and this duo surfaces as best in class option.

Below are some of the quotes from company officials:

“NeoGenomics has world-class scientific talent, significant oncology trial experience, and a broad geographic presence that will allow us to further enhance our global laboratory services for oncology trials,” said Christopher Fikry, M.D., executive vice president of PPD Laboratories. “Working with NeoGenomics will enable us to jointly provide a premier global oncology and specialty laboratory solution for our customers.”

“We are pleased to be joining PPD in this important strategic alliance and look forward to collaborating with the many scientific professionals on their team,” said Douglas VanOort, chairman and chief executive officer of NeoGenomics. “Our company is committed to saving lives by improving patient care through communication, accuracy, reliability and efficiency. That commitment aligns closely with PPD’s mission and purpose to help its customers deliver life-changing therapies that improve health.”

So what is in  for buyers:

Oncology is most watched therapeutic segment by leading pharma companies, with quicker need of solution multiple vendor involvement could be tedious task. This deal addresses that issue by bringing in multiple solutions under one roof. Strategic alliance and long term partnership would be key here.